Atrasentan: Abbott

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1240-1248

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; A 122775; A 203719; A 306552; A 308165; A 318065; ABT 546; AMBRISENTAN; ATRASENTAN; BOSENTAN; ENDOTHELIN B RECEPTOR ANTAGONIST; HORMONE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PACLITAXEL; PLACEBO; SITAXSENTAN; UNCLASSIFIED DRUG; YM 598;

ADENOCARCINOMA; ANKLE EDEMA; ANOREXIA; BLOOD TOXICITY; BRAIN EDEMA; CANCER HORMONE THERAPY; CANCER INHIBITION; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; PERIPHERAL EDEMA; PHARMACODYNAMICS; PROSTATE CANCER; PROTEINURIA; QUALITY OF LIFE; RECEPTOR AFFINITY; RECURRENT CANCER; REVIEW; RHINITIS; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR SYSTEM; HUMANS; MALE; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036707264     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. A selective endothelin receptor antagonist. 1. Discovery of A-127722. Winn M, Von Geldern TW, Opgenorth TJ, Jae HS, Tasker AS, Boyd SA, Kester JA, Mantei RA, Bal R, Sorensen BK, WuWong JR et al J Med Chem 1996 39 5 1039-1048
2. A-selective receptor antagonist. FASEB J 1996 10 Arpil 4-17 Abs 4009
3. A-selective receptor antagonist. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ J Pharmacol Exp Ther 1996 276 2 473-481
4. 239418 Potent and selective non-benzodioxole containing endothelin-A receptor antagonists. Tasker AS, Sorensen BK, Jae H-S, Winn M, Von Geldern TW, Dixon DB, Chiou WJ, Dayton BD, Calzadila S, Hernandez L, Marsh KC, Wuwong JR J Med Chem 1997 40 3 322-330
5. B selective antagonist, A-147627. Novosad EI, Wessale JL, Opgenorth TJ FASEB J 1996 10 3 Abs 4007
6. B mixed antagonists. Jae HS, Winn M, Dixon DB, Marsh KC, Nguyen B, Opgenorth TJ, Von Geldern TW J Med Chem 1997 40 20 3217-3227
7. 269852 The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodelling in Sprague-Dawley rats. Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S J Cardiovasc Pharmacol 1997 29 6 713-725 A-127722 attenuated hypertension and vascular remodeling within the pulmonary system of a hypoxic rat model.
8. 273806 Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Nelson JB, Chan Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW Cancer Res 1996 56 4 663-668 First paper to show that the ET-1 system may play a significant role in the metastasis of prostate cancer to the bone.
9. 286091 Chronic oral endothelin type A receptor antagonism in experimental heart failure. Borgeson DD, Grantham JA, Wiliamson EE, Luchner A, Redfield MM, Opgenorth TJ, Burnett JC Jr Hypertension 1998 31 3 766-770
10. 286092 Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction. Dschietzig T, Laule M, Alexiou K, Schror K, Baumann G, Stangl K Crit Care Med 1998 26 3 510-517
11. A antagonist (A-216546). Liu G, Henry K, Szczepankiewicz B, Winn M, Kozmina NS, Boyd SA, Wasicak J, Von Geldern TW, Wu-Wong JR, Chiou WJ, Dixon DB et al J Med Chem 1998 41 17 3261-3275
12. A receptor antagonist.
13. 315740 Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin: Aggravation of this phenomenon in heritable hyperlipidemia. Alexiou K, Dschietzig T, Simsch O, Laule M, Hundertmark J, Baumann G, Stangl K J Am Coll Cardiol 1998 32 6 1773-1778
14. 315741 A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: A diffusion and perfusion MRI study. Tatlisumak T, Carano RA, Takano K, Opgenorth TJ, Stotak CH, Fisher M Stroke 1998 29 4 850-857 Evidence that A-127722 exhibits neuroprotectant properties that appear independent of vascular effects.
15. 319405 American Chemical Society 217th National Meeting (Part III) Division of Medicinal Chemistry - Endothelins, Anaheim, CA, USA. IDDB Meeting Report 1999 March 22
16. 319549 Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, Joles JA Hypertension 1999 33 1 137-144 A-127722 prevented, but failed to reverse cerebral and renal injury in stroke-prone, spontaneously hypertensive rats.
17. 326268 American Society of Clinical Oncology - 35th Annual Meeting (Part IV), Atlanta, GA, USA. McKinnon C IDDB Meeting Report 1999 May 15-18
18. 326599 ABT-627, an endothelin-receptor antagonist for refractory adenocarcinoma: Phase I and pharmacologic evaluation. Carducci M, Bowling M, Rogers T, Leahy T, Moyse D, Janus T, Padley R, Nelson J Proc Am Soc Clin Oncol 1999 18 Abs 625
19. 326601 Results of an initial phase I dose-escalation study of the endothelin-A receptor antagonist ABT-627 in patients with hormone refractory prostate cancer. Zonnenberg BA, Anbaum B, Kronemeier R, Yang F, Samra E, Janus TJ, Padley RI, Grahn A, Groenewegen G Proc Am Soc Clin Oncol 1999 18 Abs 626
20. 333071 Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Best PJ, McKenna CJ, Hasdai D, Holmes DR Jr, Lerman A Circulation 1999 99 13 1747-1752
21. B selectivity. Von Geldurn TW, Tasker AS, Sorensen BK, Winn M, Sczcepankiewicz BG, Dixon DB, Chiou WJ, Wang L, Wessale JL, Adler A, Marsh KC, Nguyen B J Med Chem 1999 42 18 3668-3678
22. B antagonists containing a diphenylmethylamine acetamide side chain. Liu G, Kozmina NS, Winn M, Von Geldern TW, Dixon DB, Nguyen B, Marsh KC, Opgenorth YJ J Med Chem 1999 42 18 3679-4689
23. A receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Jarvis MF, Wessale JL, Zhu CZ, Lynch III JJ, Dayton BD, Calzadilla SV, Padley RJ, Opgenorth TJ, Kowaluk EA Eur J Pharmacol 2000 388 1 29-35
24. 360437 Preparation of endothelin antagonist ABT-627. Wittenberger SJ, McLaughlin MA Tetrahedrob Lett 1999 40 40 7175-7178
25. 362442 Inhibition of tumor growth and angiogenesis by ABT-627 an endothelin receptor A antagonist in ovarian carcinoma xenografts. Rosano L, Salani D, Di Castro V, Nicotra MR, Varmi M, Padley RJ, Natali P, Bagnato A Proc Annu Meet Am Assoc Cancer Res 2000 41 Abs 2075
26. 363137 Endothelin-1 promotes survival in prostate and renal carcinoma cell lines by inhibition of apoptosis involving the AKT pathway. Pflug BR, Udan M S, Nelson J B Proc Annu Meet Am Assoc Cancer Res 20001 41 Abs 5241
27. B receptor activation. Piovezan AP, D'Orleans-Juste P, Souza GE, Rae GA Br J Pharmacol 2000 129 5 961-968
28. 370262 A placebo (pbo) controlled phase Ii dose-ranging evaluation of an endothelin-a receptor antagonist for men with hormone refractory prostate cancer (hrpca) and disease-related pain. Carducci MA, Vogelzang NJ, Daliani D, Dawson M, Hippensteel R, Padley RJ, Janus TJ Proc Am Soc Clin Oncol 2000 19 Abs 12151
29. A selective endothelin antagonist, in humans. Verhaar MC, Grahn AY, Van Weerdt AWM, Honing MLH, Morrison PJ, Yang YP, Padley RJ, Rabelink TJ Br J Clin Pharmacol 2000 49 6 562-573
30. 375418 Preliminary phase II results using ABT-627, an endothelin-A selective receptor antagonist, in men with symptomatic hormone refractory prostate cancer. Nelson JB, Carducci MA, Dawson M, Hippensteel RL, Padley RJ, Janus TJ, ABT 627 Clinical Study Group J Urol 2000 163 4 Suppl 159
31. 404786 Atrasentan supresses tumor induced bone remodeling in men with hormone refractory prostate cancer (HRPCa). Zonnenberg B, Janus TJ, Venetucci M, Hippensteel R, Padley RJ Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 764
32. 405176 ABT 627: An endothelin A receptor antagonist as new antitumor agent in HPV-associated cervical carcinoma. Venuti A, Rosanch L, Marcante ML, Padley R, Bagnato A Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4146
33. 407049 Drug development pipeline - ABT-627, Kaletra, MC-4 receptor antagonists, Abbott, and Ancrod. Abbott Laboratories Company Communication 2001 April 25
34. 409615 The endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer Nelson JB, Carducci MA, Padley RJ, Janus T, Humerickhouse R, Hippensteel R Proc Am Clin Oncol 2001 20 1 Abs 12
35. 409892 Endothelin A receptor blockade inhibits osteoblastic metastases Guise T, Grubbs B, Cui Y, Wu-Wong J, Wessale J, Padley R, Janus T, Yin J Proc Am Assoc Clin Oncol 2001 20 1 Abs 331
36. 410596 The selective endothelin-A receptor antagonist atrasentan improves quality of life adjusted time to progression (QATTP) in hormone refractory prostate cancer patients. Singh A, Padley RJ, Ashraf T Proc Am Soc Clin Oncol 2001 20 1 Abs 1567
37. 410415 The endothelin-A receptor antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: A multinational, randomized, double-blind, placebo controlled trial Carducci MA, Nelson JB, Padley RJ, Janus T, Hippensteel R Proc Am Assoc Clin Oncol 2001 20 1 Abs 694
38. 414666 Abbott will continue to study prostate cancer drug atrasentan for early-stage/prevention. FDC Reports Pink Sheet 2001 63 27 22-23
39. A antagonists. Jae HS, Winn M, Von Geldern TW, Sorensen BK, Chiou WJ, Nguyen B, Marsh KC, Opgenorth TJ J Med Chem 2001 44 23 3978-3984
40. 443479 Abbott Laboratories: SG Cowen Health Care Conference Abbott Laboratories Company Presentation 2002 March 12
41. 452621 Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer: Follow-up to study M96-594. Carducci MA, Nelson JB, Humerickhouse R, Weinberg M, Schmitt J, Nabulsi A Proc Am Soc Clin Oncol 2002 21 1 Abs 708 Follow-up of phase II trial with atrasentan suggesting phase III trials are warranted.
42. 454058 Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ et al J Clin Oncol 2002 20 8 2171-2180
43. 454274 Multiple-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Dutta S, Samara E, Lain W, Granneman GR, Leese PT, Padley RJ Clin Drug Invest 2001 21 2 129-136
44. 454310 The endothelin-A receptor antagonist atrasentan improves time to clinical progression in hormone refractory prostate cancer patients: A randomized, double-blind, multi-national study. Nelson JB, Carducci MA, Zonnenberg B, Breul J, Padley RJ, Janus T, Hippensteel R J Urol 2001 165 5 Abs 688
45. 454326 Atrasentan suppresses tumor induced bone remodeling in men with hormone refractory prostate cancer (HRPCa). Zonnenberg B, Janus TJ, Venetucci M, Hippensteel R, Padley RJ Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 764
46. 457800 Abbot Laboratories earnings conference call-second quarter 2002. Abbott Laboratories Company Presentation 2002 July 11
47. 457845 Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ J Clin Pharmacol 2001 41 4397-403
48. 457847 'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects. Chiou WJ, Wessale JL, Von Geldern T, Opgenorth TJ, Wu-Wong JR J Cardiovasc Pharmacol 2000 36 5 Suppl 1 S48-52
49. A receptors in long-term arterial pressure homeostasis in conscious nonhuman primates. Reinhart GA, Preusser LC, Opgenorth TJ, Wegner CD, Cox BF Am J Physiol Regul Integr Comp Physiol 2000 279 5 R1701-1706
50. A receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans. Honing ML, Hijmering ML, Ballard DE, Yang YP, Padley RJ, Morrison PJ, Rabelink TJ J Am Soc Nephrol 2000 11 8 1498-504
51. A receptor selectivity. Boyd SA, Mantei RA, Tasker AS, Liu G, Sorensen BK, Henry KJ Jr, Von Geldern TW, Winn M, Wu-Wong JR, Chiou WJ, Dixon DB et al Bioorg Med Chem 1999 7 6 991-1002
52. A receptor subtypes in rabbit arteriolar smooth muscle. Curtis TM, Scholfield CN Br J Pharmacol 2001 134 8 1787-1795
53. 457928 Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A J Am Coll Cardiol 2002 39 9 1555-1561
54. 459517 Atrasentan delayed PSA progression in a phase II trial of men with hormone refractory prostate cancer. Schulman C, Nelson JB, Weinberg MA, Humerickhouse RA, Schmitt JL, Nabulsi AA J Urol 2002 167 5 Abs 102648
55. 459520 Abbott Laboratories - 2Q02 results: No time to be selling. Reicin GM, Wittes J, Shankar R Morgan Stanley Dean Writer 2002 July 18 1-24